Genocea Biosciences Highlights Key Progress in the Development of its First Vaccine Candidate, Targeting HSV-2

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences announced today the results of two studies that showcase the company’s efforts to develop the first-ever therapeutic vaccine for HSV-2 (herpes simplex virus type 2). In a poster presentation made at Immunology 2012, the 99th Annual Meeting of the American Association of Immunologists, researchers demonstrated the ability of Genocea’s vaccine candidate (GEN-003) to elicit strong and lasting B and T cell immune responses in preclinical studies. A second presentation highlighted novel insights supporting the hypothesis that a vaccine strategy targeting T cells may provide a significant therapeutic benefit to patients.